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Abstract
Background: Migraine is the most prevalent neurological disorder worldwide and ranked sixth among all diseases in
years lived with disability. Overall preventive anti-migraine therapies have an effect in one patient out of two at the most,
many of them being endowed with disabling adverse effects. No new disease-modifying drugs have come into clinical
practice since the application to migraine of topiramate and botulinum toxin, the latter for its chronic form. There is thus
clearly a need for more effective treatments that are devoid of, or have acceptable side effects. In recent years, scientific
progress in migraine research has led to substantial changes in our understanding of the pathophysiology of migraine and
paved the way for novel non-drug pathophysiological-targeted treatment strategies.
Overview: Several such non-drug therapies have been tested in migraine, such as oxidative phosphorylation enhancers,
diets and non-invasive central or peripheral neurostimulation. All of them are promising for preventive migraine treat-
ment and are quasi-devoid of side effects. Their advantage is that they can in theory be selected for individual patients
according to their pathophysiological profile and they can (and probably should) be combined with the classical pharma-
cological armamentarium.
Conclusion: We will review here how knowledge of the functional anatomy and physiology of migraine mechanisms
holds the key for more specific and effective non-pharmacological treatments.
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Introduction
Migraine is the most prevalent neurological disorder
worldwide and ranked sixth in the most disabling dis-
eases aﬀecting mankind. There are major problems for
clinicians in treating migraine with the available pre-
ventive therapies. Firstly, the average eﬃcacy rate of
any prophylactic agent does not exceed 50%, and sec-
ondly, almost all prophylactic drugs are associated with
cumbersome and sometimes intolerable adverse eﬀects.
Moreover, episodic migraine may evolve into a chronic
form (>15 days/month with headache) that often
becomes resistant to treatment, which heavily impacts
on the patients’ quality of life. It is fortunate therefore
that numerous non-pharmacological treatments for
migraine have been tested in recent years. They include
the so-called nutraceuticals (riboﬂavin, coenzyme
Q10 (CoQ10), magnesium, etc.), dietary interventions
(low calorie, vegan, ketogenic, etc.) and peripheral
nerve or transcranial neurostimulation. Many of these
therapies still lack evidence-based data from large, ran-
domized, placebo-controlled trials and are thus not
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widely used or accepted. The available clinical data
are presented in other articles of this special issue
(see (1–3)).
Dietary interventions
Inﬂammation is a potential unifying factor that may
explain the link between diet and migraine. In fact, all
factors implicated in the diet–migraine relationship
may share inﬂammation as a common target. Levels
of inﬂammatory cytokines are higher in obese subjects
(4) and are normalized by weight loss, together with
leukocyte counts and oxidative stress (5,6). Altered
insulin metabolism in migraineurs may be related to
adipocytokines (7) and nitric oxide stress (8), both of
which promote inﬂammation. Adipocytokines are adi-
pocyte-derived cytokines involved in energy homeosta-
sis, obesity and diabetes. In particular, two subtypes of
adipocytokines – leptin and adiponectin – could be
involved in migraine pathophysiology. Leptin, which
also has vasoactive and inﬂammatory properties, is
higher in hyperinsulinemic migraineurs (9). High-
molecular-weight adiponectin has been shown to
induce inﬂammatory cytokine secretion and is related
to chronic migraine (7,10). Interestingly, the ﬂunarizine
and amitriptyline-induced side eﬀect of becoming over-
weight may be related to pharmacological induction of
higher levels of insulin, leptin and C-peptide (11).
Higher levels of insulin and leptin could in turn coun-
teract treatment eﬃcacy, and long-term use might
worsen pre-existing migraine.
Several speciﬁc diets are proposed as eﬀective stra-
tegies for improving migraine: low-sodium diet (12),
deprivation diet (13), vegan diet (14) and ketogenic
diet (KD) (15,16). The KD is particularly noteworthy
with respect to migraine treatment. Classically, KD is
regarded as a high-fat, low-carbohydrate diet that pro-
motes ketone body (KB) production as an energetic
substitute for glucose. It was adopted in the 1920s to
treat drug-resistant epilepsy (17) and migraine (18).
Over recent years, an alternative KD regimen, called
very-low-calorie KD (VLCKD), which mimics fasting
by restricting carbohydrates and fats, was proposed to
achieve rapid weight loss. There are several aspects
of VLCKD that could have beneEcial eGects on
overweight migraineurs (15,16). KBs in this scenario
may act on migraine through several mechanisms of
action: ﬁrstly, modulating neuronal excitability (17);
secondly, tapering neural inﬂammation (19); and
thirdly, enhancing mitochondrial energetic metabolism
(16). Available clinical trials of diets for migraine are
reviewed elsewhere in this special issue of Cephalalgia
(see (1)).
Nutraceuticals
The rationale for using high-dose nutraceutical supple-
ments, such as riboﬂavin, CoQ10 and magnesium, in
migraine prophylaxis comes from phosphorus-31
magnetic resonance (MR) spectroscopy studies show-
ing that an unstable state of brain metabolism may be
present in migraine patients. In fact, mitochondrial oxi-
dative phosphorylation (OXPHOS; i.e. the energy
reserve) is reduced by 25–30% interictally in the
brains of migraineurs with or without aura (20,21).
Mitochondria produce free radicals through
OXPHOS and adenosine triphosphate. On the other
hand, mutations in mitochondrial DNA (mtDNA)
were reported in migraine associated with stroke epi-
sodes (22), and increased numbers of sequence variants
were detected in the non-coding control regions of
mtDNA in migraineurs with occipital stroke (23).
Two single-nucleotide polymorphisms in the non-
coding mtDNA were found to be more prevalent in
children with migraine and cyclic vomiting (24), and
migraine is highly prevalent in carriers of the mtDNA
3243A>G (MELAS) mutation (25).
Large doses of riboﬂavin (400mg/day), like those
given to patients with MELAS or mitochondrial myo-
pathies, are assumed to increase activity of mitochon-
drial complexes 1 and 2, thereby improving clinical and
biochemical abnormalities (26). CoQ10 is an essential
cofactor of the electron transport chain in mitochon-
dria (27). Administration of CoQ10 also increased com-
plex-1 activity in a mouse model of Parkinson’s disease
(28). Mg2þ is the foremost regulator of metabolism,
largely through its role as a cofactor for all phosphoryl
transfers in the cell (29). Low brain magnesium levels
have been detected using in vivo phosphorus-31 MR
spectroscopy during (30) and between (31) migraine
attacks, and low magnesium levels were also found in
various other biological tissues (32,33). Impaired
OXPHOS performance was the rationale for the use
of OXPHOS enhancers (riboﬂavin, CoQ10, Mg) as
prophylactic therapies in migraine. Available clinical
trials of OXPHOS enhancers in migraine are reviewed
elsewhere (1).
Neuromodulation
Transcranial magnetic stimulation and transcranial
direct current stimulation
The rationale for the use of non-invasive neuromodu-
latory techniques comes from evidence that abnormal
cortico-thalamic information processing characterizes
the brains of migraine patients and that transcranial
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magnetic stimulation (TMS) and transcranial direct
current stimulation (tDCS) are able to either activate
or inhibit the underlying cerebral cortex. The abnormal
information processing is characterized between attacks
by a normal-to-low amplitude response to low numbers
of stimuli, followed by an amplitude increase during
prolonged stimulation (i.e. potentiation), contrasting
with an amplitude decrease (i.e. habituation) in
normal subjects. This has been observed for cortical
responses to all sensory modalities, with the exception
of olfaction. Abnormal cortical responsivity was also
detected with power mapping of the resting electro-
encephalogram (EEG) as decreased alpha but increased
theta power, and EEG hypersynchronization during
repetitive photic stimulation (34). Abnormal rhythmic
activity between the thalamus and cortex, namely tha-
lamocortical dysrhythmia, which decrease preactiva-
tion levels of sensory cortices, may be the underlying
pathophysiological mechanism for the habituation
deﬁcit in migraine (see (35) for a review).
In migraine patients, activation of the visual or sen-
sorimotor cortices with high-frequency repetitive TMS
(rTMS) was able to increase both the amplitude of the
ﬁrst visual (VEP) and somatosensory evoked responses
and habituation over successive blocks of responses for
several hours. By contrast, inhibiting low-frequency
rTMS had negligible eﬀects (36,37). Moreover, activat-
ing the sensorimotor cortex with rTMS was also able to
increase the interictal low thalamo-cortical drive in
migraine (37,38). Similarly, cortico-striato-thalamo-
cortical functional network activity increased in con-
trols after anodal tDCS over M1, but not after cathodal
or sham tDCS (39). Five consecutive daily sessions of
activating rTMS over the visual cortex of migraineurs
increased VEP habituation for long periods, lasting up
to a few days (40). In accordance with these rTMS
studies, Vigano` et al. (41) reported in migraine patients
and controls that VEP habituation increased immedi-
ately after an activating anodal tDCS over the visual
area. Anodal tDCS also decreased magnetophosphene
thresholds in patients and controls, while cathodal
tDCS increased these thresholds in healthy subjects,
but not signiﬁcantly so in migraine patients (42).
In animal models, single-pulse TMS was reported to
be eﬀective (43) or ineﬀective (44) for inhibiting cortical
spreading depression (CSD) occurrence. Anodal tDCS
was able to signiﬁcantly modify the propagation vel-
ocity of CSD (45), especially when the underlying
cortex was previously inhibited (46).
Taken together, the accruing knowledge about cor-
tical responsivity and the cyclic functional and struc-
tural changes occurring in certain cerebral networks
in migraine, combined with the technological advances
in neuromodulation device development and the data
showing their eﬀects on brain activity, paved the way
for clinical trials of transcranial neurostimulation meth-
ods for the acute and preventive treatment of migraine.
Peripheral (cranial) nerve stimulations
The Ad and C ﬁbers of the trigeminovascular system
that innervates the meninges and is thought to be
responsible for the headache in migraine converge in
the spinal trigeminal nucleus, with similar nociceptive
ﬁbers coming from the somatic portion of the ophthal-
mic nerve and the greater occipital nerve (47). There is
thus a priori an anatomical rationale for applying neu-
rostimulation to somatic branches of the ophthalmic
division of the trigeminal nerve and/or of the C2 der-
matoma, with the objective of modifying the activity of
trigeminovascular nociceptors in the spinal trigeminal
nucleus. Electrophysiological and imaging studies have
indeed shown functional changes of the trigeminal noci-
ceptive system over the migraine cycle. In a functional
MR imaging (MRI) study of the response to nocicep-
tive stimuli of the nasal mucosa, the blood oxygen level-
dependent signal in the spinal trigeminal nucleus
increased with closer vicinity to the next attack (48).
The blink reﬂex (BR), which is highly sensitive to
changes in trigeminal activity, lacks habituation in
migraineurs between attacks (49–51), but its recovery
curve is normal (52), indicating absence of sensitization.
During migraine attacks, sensitization and reduced
pain thresholds were observed on the aﬀected side com-
pared to the non-aﬀected side after noxious radiant
CO2 laser stimulation in the face (53) and with the
nociception-speciﬁc BR (54).
The precise mechanism of action in migraine of per-
ipheral neurostimulation methods still needs to be fur-
ther studied. Nevertheless, some hints about possible
mechanisms come from the known anatomical–
functional organization of the trigeminovascular
system and from some imaging studies in treated
patients. Electrical stimulation of somatic branches of
the ophthalmic nerve or of the greater occipital nerve
activates large Ab, whose collaterals could inhibit
second-order nociceptors in the spinal trigeminal
nucleus via a ‘‘gate control’’ mechanism. It also stimu-
lates some Ad ﬁbers that converge on the same nucleus
with visceral meningeal trigeminovascular aﬀerents and
could induce a phenomenon of ‘‘after-suppression’’ in
trigeminal nociceptors (i.e. suppression of nerve cells
ﬁring after a period of prolonged stimulation) (55).
Imaging studies in chronic migraine (56) and cluster
headache patients (57) stimulated with a percutan-
eously implanted suboccipital stimulator, however,
Coppola et al. 3
show that peripheral neurostimulation modulates cen-
tral areas involved in pain control, which might be
responsible for its therapeutic eﬀect. Overall, these clin-
ical, structural and functional data have paved the way
for targeting cranial nerves with neuromodulatory
techniques.
Vagus nerve stimulation
Vagus nerve stimulation (VNS) with implanted elec-
trodes wrapped around its cervical portion is eﬀective
as an add-on treatment in medically intractable epilepsy
and major depression. Several experimental studies in
animals and observational reports in humans have also
provided a rationale for using VNS in migraine ther-
apy. The visceral aﬀerent ﬁbers that are the main ﬁber
population of the vagus nerve in the neck project via
the nucleus of the solitary tract to various central ner-
vous system (CNS) centers that are known to be
involved in migraine pathophysiology, such as the thal-
amus (58,59), the brainstem monoaminergic nuclei (60)
and the limbic and somatosensory cortices (61). In
freely moving cats, VNS with implanted electrodes
had transient eﬀects on neuronal activity in primary
visual areas, causing a delay in the establishment of
visual habituation (62), a phenomenon that is known
to be dysfunctional in migraine between attacks (35).
Moreover, VNS can modulate nociception, for instance
by increasing pain thresholds (63), by reducing accruing
pain associated with trains of consecutive stimuli
(‘‘wind-up’’) (64) and also by modulating neuronal
activity in the spinal trigeminal nucleus (65). The dir-
ection of the VNS-related eﬀects on nociception
induced by stimulation of the transected vagus nerve
in animals depends, however, on the stimulation proto-
col. Overall, these experimental studies suggest that the
anti-nociceptive eﬀect of VNS might rely on central
inhibition of pain rather than modiﬁcations of periph-
eral nociceptive mechanisms.
Several case reports have shown that VNS with the
implantable cervical stimulation system can improve
comorbid migraine in patients treated for intractable
epilepsy (66–69). Invasive VNS was also reported to
be eﬀective in some chronic migraine patients (70,71).
The available clinical trials of TMS, tDCS and per-




Migraine is commonly regarded as a bio-behavioral dis-
order resulting from a combination of behavioral and
biological (CNS dysfunction) factors. The behavioral
factors refer to actions or reactions of the individual
in response to certain internal or external stimuli,
such as stress. Repeated abnormal or excessive reac-
tions can cause or worsen the disorder. As mentioned
above, the migraineur’s brain hyper-reacts to prolonged
repeated stimuli, whatever its sensory modality. It also
does this during cognitive tasks (see (35) for a review).
That the altered information processing in migraine
between attacks is associated with limbic system
dysfunction is illustrated by several functional MRI
studies. They showed, for example, interictal abnorm-
alities in the functional resting state of aﬀective pain
regions that belong to multisensory–discriminative,
cognitive/executive and integrative domains (72–74),
strengthening the view that migraine is a bio-behavioral
disorder.
Behavioral therapies aim at changing speciﬁc actions
and use techniques to reduce or eliminate behaviors
that create discomfort and to increase or acquire behav-
iors that promote a better quality of life (see Andrasik
in this issue). Besides classical cognitive–behavioral
therapies that are useful in migraine, particularly
when associated with preventive drug therapy (75),
the behavioral paradigm can be used to change and
control measurable brain activities, which is a method
that is called ‘‘neurofeedback’’ (NFB). NFB combines
behavioral techniques and neurophysiological record-
ings to teach the individual how to control various
aspects of their own brain activity, such as spontaneous
or evoked EEG, and to promote self-regulatory pro-
cesses, such as cognitive performance, stress levels,
emotional functioning and behavior (76). Although
the underlying neural mechanisms of self-regulation
are not fully understood, it was proposed that self-reg-
ulation of brain activity is based on neuroplasticity
mechanisms promoting short- and long-term changes
in the bioelectric activity (77) of several interconnected
cerebral areas, including, for instance, subcortical
regulatory structures (76,78,79) and various cortical
networks, including executive, salient and attentive net-
works (80,81). Because several of the latter subcortico-
cortical brain networks are known to be dysfunctional
in migraine, there is a biological rationale for using
NFB in migraine therapy.
Conclusion
Migraine is a complex bio-behavioral disorder asso-
ciated with cycling abnormalities of the function and
structure of the brain networks involved in information
processing, limbic and pain control, but also with
a deﬁcient mitochondrial energy metabolism.
Pathophysiological ﬁndings in migraine have identiﬁed
a number of brain targets that are amenable to selective
modiﬁcation by nutraceuticals, diets, external neurosti-
mulation or to more global changes in cortical
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networks by cognitive–behavioral and NFB therapy.
They can be summarized as follows (see also Figure 1):
. Recent data indicate that, in subgroups of patients,
migraine is related or at least correlated with the
metabolic syndrome spectrum. The evidence for
this is an association between obesity, insulin resist-
ance and migraine. All of these pathologies are
associated with a pro-inﬂammatory state. Diﬀerent
dietetic approaches have been tested to treat
migraine and were found to be beneﬁcial (Orr (1),
this issue).
. Mitochondrial dysfunction resulting in impaired
OXPHOS metabolism may play a role in migraine
pathogenesis. Previous studies have proven the eﬃ-
































Figure 1. Scheme of migraine pathophysiological targets in migraine for non-pharmacological interventions. Diets could act by
modulating neuronal excitability (a), mitigating sterile inflammation at the level of the trigeminovascular system (b) or enhancing
mitochondrial energy metabolism (c). Nutraceuticals enhancing oxidative phosphorylation can augment the activity of mitochondrial
complexes 1 and 2 (c). rTMS and tDCS are able to modify cortical responsivity (a) and thalamocortical circuits (d). Transcutaneous
nerve stimulation may act by inducing long-term plasticity changes in central pain control centers (e). Vagus nerve stimulation is able to
modulate the thalamus (d), the brainstem monoaminergic nuclei (f) and the cerebral cortex (a). Neurofeedback may act via neuro-
plastic changes in interconnected cerebral areas, such as the thalamus (d), brainstem (f) and various cortical networks (a), including
executive, salient and attentional networks.
rTMS: repetitive transcranial magnetic stimulation; tDCS: transcranial direct current stimulation.
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CoQ10 and magnesium in migraine prophylaxis.
Whether the KD is suitable as a long-term strategy
for migraine must be determined (see Orr (1), this
issue).
. Lack of habituation at the trigeminal and cortical
levels and low thalamocortical drive were demon-
strated between attacks (35). Because these abnorm-
alities can be partly reversed by the modern minimally
invasive (2) or non-invasive neurostimulation tech-
niques (see Schoenen et al. (3), this issue), many
research groups have tested occipital nerve stimula-
tion (ONS), rTMS, tDCS and transcutaneous nerve
stimulation for migraine treatment, but with discrep-
ant results and scarce sham-controlled trials.
. Migraine seems to be associated with interictal
abnormal reactivity of spontaneous EEG and slow
cognitive cortical potentials. This a rationale for the
few studies that tested behavioral training programs
such as NFB to treat migraine.
While all classical preventive anti-migraine drugs
have multiple neurobiological eﬀects and their sites of
action in the pathophysiological cascade of migraine
are uncertain, most of the non-pharmacological
migraine therapies target one or a few of the facets
of migraine pathophysiology, which may explain
why their eﬀect sizes are moderate overall. They
have two major advantages, however. First, in future
studies, they can (and should) be selected according to
the pathophysiological phenotype of the individual
patient, and second, because of their excellent tolerance
and safety, most of them can be combined with a
drug treatment or with another non-pharmacological
therapy.
Clinical implications
. Although knowledge on migraine mechanisms has greatly increased in the last decade, there have been no
signiﬁcant advances in the marketed pharmacological treatment of the disorder.
. The available clinical data for alternative non-drug treatments are summarized in other articles of this
special issue. Many of them still lack deﬁnitive evidence from placebo-controlled trials, but are able to
target speciﬁc aspects of migraine pathophysiology.
. We review here the rationale for using nutraceuticals and neurostimulation methods in migraine therapy and
illustrate how they open the perspective for treatment strategies customized to the pathophysiological proﬁle
of the individual migraine patient.
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